Vikas Dandekar
Editor, Pharma and Life Science at ET Prime
Journalist - Indian pharma & healthcare. Views own [email protected]
Articles
-
1 month ago |
economictimes.indiatimes.com | Teena Thacker |Vikas Dandekar
• Minimising use of animals in testing The government is giving final touches to a revised set of regulations to set stringent quality standards for research and manufacture of biosimilar drugs , which are emerging as a mainstay for treatment of cancers and autoimmune diseases among others.Biosimilars are medicines based on living cells and are very similar—but not identical—to originally invented biological drugs, or biologics.Currently under consultations, the ‘Guidelines on Similar...
-
Feb 22, 2025 |
economictimes.indiatimes.com | Teena Thacker |Vikas Dandekar
The Drug Controller General of India has ordered a ban on the production of tapentadol and carisoprodol, the two drugs earlier found to be illegally exported to African nations, such as Ghana and Nigeria, and blamed for causing a serious public health crisis of opioid addiction.The issue came under the spotlight as part of a recent BBC investigation that exposed a racket, where an Indian producer was exporting the unlicensed addictive combination.Tapentadol is a strong opioid and is used to...
-
Jan 6, 2025 |
economictimes.indiatimes.com | Vikas Dandekar
MUMBAI: Intas Pharmaceuticals ' acquisition of Udenyca for up to $558.4 million (about Rs 4,784 crore) will pit it against other leading biosimilar makers like Biocon Pfizer , Fresenius Kabi and Sandoz in the fast-growing global market for oncology treatment.In one of the biggest deals worldwide for a biosimilar brand, Ahmedabad-based Intas agreed to buy Udenyca-the brand name for medication pegfilgrastim-cbqv-from US-based Coherus BioSciences .
-
Dec 19, 2024 |
insights.citeline.com | Jessica Merrill |Vikas Dandekar
Sun Pharma’s $4B Ranbaxy Buy Brings Consumer Products Business With New Growth FocusIn a landmark deal that fits the “made-for-each-other” tag, India’s Sun Pharma agreed to acquire all of Ranbaxy in a $4 billion transaction. While Ranbaxy can hope for a fresh lease on life with tighter regulatory operations under Sun Pharma, analysts said Sun needed to go for a big catch to sustain growth momentum.
-
Nov 8, 2024 |
flipboard.com | Vikas Dandekar
19 hours agoIt's not all related to menopause, experts discovered. Talk about a birthday gift I wish I could mark “return to sender.” Just two weeks shy of turning 42, this ominous headline crossed my Slack: “Human aging accelerates dramatically at age 44 and 60.” Now, I’m no great mathematician, but even I can …
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →X (formerly Twitter)
- Followers
- 13K
- Tweets
- 30K
- DMs Open
- Yes
RT @Teensthack: A huge number of MSME pharma companies are manufacturing substandard drugs. According to the data by India’s drug regulator…
RT @EconomicTimes: If your journey reflects #leadership, #resilience, and results, nominate yourself to be part of the #ET40UnderForty list…
RT @kiranshaw: India must consider adopting innovative methods such as organoids, in vitro, and in-silico methods as part of regulatory ref…
